Determination of Serum Antibody to<i>Bordetella pertussis</i>Adenylate Cyclase Toxin in Vaccinated and Unvaccinated Children and in Children and Adults with Pertussis

Cherry, James D.; Xing, Dorothy; Newland, Penny; Patel, Kashmira; Heininger, Ulrich; Corbel, Michael J.

doi:10.1086/381204

Cited by 45 publications

(50 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Primary infections of children with either B. pertussis or B. parapertussis hu stimulate a vigorous serum antibody response to CyaA (153). In contrast, children immunized with DTP or DTaP vaccines who later became vaccine failures and developed pertussis had only minimal serum antibody responses to CyaA.…”

Section: Virulence Determinantsmentioning

confidence: 99%

See 1 more Smart Citation

Molecular Pathogenesis, Epidemiology, and Clinical Manifestations of Respiratory Infections Due toBordetella pertussisand OtherBordetellaSubspecies

2005

Self Cite

View full text Add to dashboard Cite

Bordetella respiratory infections are common in people (B. pertussis) and in animals (B. bronchiseptica). During the last two decades, much has been learned about the virulence determinants, pathogenesis, and immunity of Bordetella. Clinically, the full spectrum of disease due to B. pertussis infection is now understood, and infections in adolescents and adults are recognized as the reservoir for cyclic outbreaks of disease. DTaP vaccines, which are less reactogenic than DTP vaccines, are now in general use in many developed countries, and it is expected that the expansion of their use to adolescents and adults will have a significant impact on reducing pertussis and perhaps decrease the circulation of B. pertussis. Future studies should seek to determine the cause of the unique cough which is associated with Bordetella respiratory infections. It is also hoped that data gathered from molecular Bordetella research will lead to a new generation of DTaP vaccines which provide greater efficacy than is provided by today's vaccines

show abstract

Section: Virulence Determinantsmentioning

confidence: 99%

“…Following infection, antibodies develop to many B. pertussis antigens including PT, FHA, PRN, FIM2/3, CyaA, and LPS (149,153,346,347,490,666,757,758,767). Agglutinating antibodies (agglutinins) develop specifically to FIM2/3, PRN, and LPS.…”

Section: Pathogenesis and Immunitymentioning

confidence: 99%

Molecular Pathogenesis, Epidemiology, and Clinical Manifestations of Respiratory Infections Due toBordetella pertussisand OtherBordetellaSubspecies

2005

Self Cite

View full text Add to dashboard Cite

show abstract

“…In one study, although a vigorous antibody response to adenylate cyclase toxin was elicited by natural infection in previously unvaccinated patients, the response was very limited in patients who had been vaccinated. 52 Therefore, diagnosis by means of serologic testing may be difficult in vaccinated or adult patients.…”

Section: Background Incidence ↔ ↔mentioning

confidence: 99%

Diagnosis and management of pertussis

Tozzi¹

2005

Canadian Medical Association Journal

View full text Add to dashboard Cite

PERTUSSIS IS INCREASING IN FREQUENCY among children too young to be vaccinated and among adolescents and adults. This increase is due mainly to waning immunity among vaccinated individuals, who become susceptible during adolescence and adulthood and maintain the circulation of Bordetella pertussis. Infants are at highest risk of severe illness requiring hospital admission, complications and death. The clinical presentation in adolescents, adults and vaccinated individuals may be atypical, with paroxysmal cough of short duration or simply a persistent cough. Culture and polymerase chain reaction may be used to identify B. pertussis infection, but their sensitivity is high only in the early phase of the disease. Serologic tests are not standardized for the diagnosis of pertussis, and their clinical application is limited. Erythromycin is still considered in some countries to be the “gold standard” for therapy and prophylaxis; however, azithromycin and clarithromycin seem equally efficacious and are associated with fewer side effects

show abstract

“…An immune response to this toxin may therefore be important in preventing colonization of the host by B. pertussis. The immunogenic properties of CyaA are indicated by reports of anti-CyaA antibodies in sera from convalescent patients and patients vaccinated with WCVs (1,6,10,14). Immunization with CyaA, purified from B. pertussis or in recombinant form from Escherichia coli, protected mice against intranasal challenge with virulent B. pertussis (6,18,19).…”

mentioning

confidence: 99%

Effect of Different Forms of Adenylate Cyclase Toxin ofBordetella pertussison Protection Afforded by an Acellular Pertussis Vaccine in a Murine Model

et al. 2006

Self Cite

View full text Add to dashboard Cite

Four recombinant forms of the cell-invasive adenylate cyclase toxin (CyaA) of Bordetella pertussis were compared for the ability to enhance protection against B. pertussis in mice when coadministered with an acellular pertussis vaccine (ACV). The four forms were as follows: fully functional CyaA, a CyaA form lacking adenylate cyclase enzymatic activity (CyaA*), and the nonacylated forms of these toxins, i.e., proCyaA and proCyaA*, respectively. None of these forms alone conferred significant (P > 0.05) protection against B.

show abstract

Determination of Serum Antibody toBordetella pertussisAdenylate Cyclase Toxin in Vaccinated and Unvaccinated Children and in Children and Adults with Pertussis

Cited by 45 publications

References 19 publications

Molecular Pathogenesis, Epidemiology, and Clinical Manifestations of Respiratory Infections Due toBordetella pertussisand OtherBordetellaSubspecies

Molecular Pathogenesis, Epidemiology, and Clinical Manifestations of Respiratory Infections Due toBordetella pertussisand OtherBordetellaSubspecies

Diagnosis and management of pertussis

Effect of Different Forms of Adenylate Cyclase Toxin ofBordetella pertussison Protection Afforded by an Acellular Pertussis Vaccine in a Murine Model

Contact Info

Product

Resources

About